Table 1.
Baseline Characteristics of AML Patients
| Characteristics | Total n=38 | Leukapheresis + Chemotherapy n=11 | Chemotherapy Only n=27 | P value |
|---|---|---|---|---|
| Age (years) (SD) | 42.45 (15.52) | 40.82 (8.67) | 43.11 (17.67) | 0.685 |
| Gender | 0.762 | |||
| Male (%) | 17 (44.7%) | 4 (36.4%) | 13 (48.1%) | |
| Female (%) | 21 (55.3%) | 7 (63.6%) | 14 (51.9%) | |
| Body Mass Index (Kg/m2) (median) | 21.125 (11.98–36.57) | 21.96 (11.98–30.08) | 21.71 (12.33–36.57) | 0.552 |
| Hemoglobin (g/dl) (SD) | 7.527 (2.227) | 6.694 (2.165) | 7.866 (2.200) | 0.144 |
| MCV (Femtolitre) (SD) | 87.458 (5.689) | 87 (7.1255) | 87.644 (5.140) | 0.756 |
| Leukocyte (mm3) (median) | 205,835 (105,000–847,000) | 353,830 (143,360–847,000) | 170,930 (105,000–369,100) | 0.003 |
| Thrombocyte (mm3) (median) | 39,550 (6000–665,000) | 57,900 (6000–125,000) | 34,000 (7540–665,000) | 0.509 |
| Blast (%) (median) | 90 (42–97) | 90 (54–97) | 90 (42–96) | 0.485 |
| Creatinine (mg/dl) (median) | 1.08 (0.46–6.00) | 1.41 (0.56–5.48) | 1.03 (0.46–6.00) | 0.573 |
| Respiratory leukostasis (%) | 21 (55.3%) | 2 (18.2%) | 19 (70.4%) | 0.010 |
| Central Nervous System Leukostasis (%) | 20 (52.6%) | 5 (45.5%) | 15 (55.6%) | 0.836 |
| Cardiovascular Leukostasis (%) | 10 (26.3%) | 3 (27.3%) | 7 (25.9%) | 1.000 |
| Gastrointestinal Leukostasis (%) | 22 (57.9%) | 4 (36.4%) | 18 (66.7%) | 0.176 |
| Tumor Lysis Syndrome (%) | 15 (39.5%) | 3 (27.3%) | 12 (44.4%) | 0.538 |
| Disseminated Intravascular Coagulation (%) | 13 (34.2%) | 3 (27.3%) | 10 (37%) | 0.843 |
| Chronic Comorbidities (%) | 14 (36.8%) | 2 (18.2%) | 12 (44.4%) | 0.250 |